Skip to content
Search

Latest Stories

UCL proposes simple daily pill that prevents heart attacks and strokes

Moving from treatment to prevention on a grand scale.

daily pill

This new approach could make life-saving medication accessible to millions

iStock

Imagine a single daily pill that could dramatically cut your risk of heart attacks and strokes. Sounds almost too good to be true, right? Well, scientists from University College London (UCL) believe this vision could soon be a reality. The breakthrough "polypill" combines a statin and three blood pressure-lowering medications, promising to transform how we prevent cardiovascular diseases, one of the UK’s biggest health challenges.

A revolutionary approach to heart disease prevention


Heart disease and strokes are silent killers, claiming thousands of lives each year. The current NHS Health Check programme helps identify at-risk individuals, but the system isn’t reaching nearly enough people. Fewer than half of those eligible even attend their appointments. This means that countless lives could be saved if more people were offered preventive treatment.

That’s where the polypill comes in. Rather than relying on complex risk assessments, UCL experts suggest a much simpler approach: offering the polypill to everyone aged 50 and over. No lengthy health checks, just the pill. This could make it a revolutionary tool in preventing heart attacks and strokes on a massive scale.

What exactly is the polypill?

The polypill is a combination of four well-established drugs: a statin to lower cholesterol and three different blood pressure-lowering medications. The idea of combining these drugs isn’t new; it dates back to a 2003 study that suggested a polypill could prevent up to 80% of heart attacks and strokes in people over 55. Since then, various trials have backed up these claims.

Professor Aroon Hingorani, a leading UCL researcher, explains that most heart attacks and strokes happen in people with “average” risk levels, which means the current system of identifying high-risk individuals often misses the mark. Offering the polypill to everyone over 50 could potentially save far more lives.

A simple, life-saving solution

One of the biggest advantages of the polypill is its simplicity. There’s no need for complicated medical assessments, just a few basic questions to check for side effects. Once that’s done, eligible people can start taking the pill, drastically reducing their risk of heart-related problems.

UCL researchers estimate that even if only 8% of people over 50 take up the offer, the health benefits would far exceed what’s currently achieved through the NHS Health Check. This new approach could make life-saving medication accessible to millions in the same way that vaccines or folic acid fortification do.

Professor Sir Nicholas Wald, another UCL co-author, compares the polypill approach to other public health programmes designed to prevent illness before it happens. “This isn’t about medicalising half the population,” Wald points out. “It’s about making sure people don’t become patients in the first place.”

Affordable, proven, and effective

The polypill is not only effective but also affordable. The medications it contains are all off-patent, meaning they’re inexpensive to produce. Despite the low cost, these drugs have a long-standing track record of success with minimal side effects. In particular, combining three blood pressure drugs at low doses reduces the risk of side effects even further while maximising the benefits.

In 2019, a landmark study in rural Iran showed that taking the polypill for five years reduced heart attacks and strokes by a third. This dramatic finding demonstrates the real-world potential of the polypill to change the game not just in the UK but globally.

What’s next for the polypill?

With such compelling evidence, the next step is figuring out how to introduce the polypill programme nationwide. UCL researchers have proposed a pilot project to evaluate how best to roll it out, looking at factors such as cost, uptake, and long-term effectiveness.

However, for this plan to become a reality, it would require policy changes. Currently, local authorities are required to offer NHS Health Checks, and a polypill programme would need to replace or supplement this. But the UCL team is confident this shift is necessary, calling the current situation “untenable.”

With over seven million people in the UK affected by cardiovascular disease, and more than 200,000 heart attacks and strokes every year, it’s clear that a new approach is desperately needed. The polypill could be that solution: a simple, affordable, and effective way to prevent countless deaths and reduce the burden on the NHS.

A new era in prevention

The polypill isn’t just another medical treatment; it could be the key to unlocking a future with fewer heart attacks and strokes. By offering this life-saving pill to everyone over 50, we could see a drastic reduction in cardiovascular diseases. The scientific evidence is strong, the potential impact is huge, and the time to act is now.

As we wait for further studies and potential rollouts, one thing is certain: prevention is always better than cure, and the polypill could very well be the future of heart disease prevention.

More For You

Spotting the signs of dementia

Priya Mulji with her father

Spotting the signs of dementia

How noticing the changes in my father taught me the importance of early action, patience, and love

I don’t understand people who don’t talk or see their parents often. Unless they have done something to ruin your lives or you had a traumatic childhood, there is no reason you shouldn’t be checking in with them at least every few days if you don’t live with them.

Keep ReadingShow less
Mounjaro price rise

Eli Lilly has agreed a discounted supply deal for its weight-loss drug Mounjaro

iStock

Mounjaro’s highest dose to rise from £122 to £247.50, not £330

Highlights:

  • Eli Lilly had announced a steep price rise of up to 170% for Mounjaro.
  • A new discount deal with UK suppliers will limit the increase for patients.
  • Pharmacies will still apply a mark-up, but consumer costs are expected to rise less than initially feared.
  • NHS pricing remains unaffected due to separate arrangements.

Eli Lilly has agreed a discounted supply deal for its weight-loss drug Mounjaro, easing fears of a sharp rise in costs for UK patients. The new arrangement means that, from September, pharmacies and private services will face smaller wholesale increases than first expected, limiting the impact on consumers.

Why the price rise was announced

Earlier this month, Eli Lilly said it would raise Mounjaro’s list price by as much as 170%, which could have pushed the highest monthly dose from £122 to £330. The company argued that UK pricing needed to align more closely with higher costs in Europe and the United States.

Keep ReadingShow less
chicken-pox-istock

The Department of Health said the rollout would reduce missed days at nursery and school, cut time parents take off work, and save the NHS about £15 million a year. (Representational image: iStock)

iStock

England to introduce free chickenpox vaccine for children from 2026

CHILDREN in England will be offered a free chickenpox vaccine for the first time from January 2026, the government has announced.

GP practices will give eligible children a combined vaccine for measles, mumps, rubella and varicella (MMRV) as part of the routine childhood vaccination schedule. Around half a million children each year are expected to be protected.

Keep ReadingShow less
Naga Munchetty urges women to prioritise their health

Naga Munchetty

Naga Munchetty urges women to prioritise their health

WHEN broadcaster and journalist Naga Munchetty began speaking openly about her experiences with adenomyosis and debilitating menstrual pain, the response was overwhelming.

Emails and messages poured in from women who had endured years of dismissal, silence and shame when it came to their health. That outpouring became the driving force behind her new book, It’s Probably Nothing, which calls for women to be heard and to advocate for themselves in a medical system that has too often ignored them.

Keep ReadingShow less
Serena Williams

Williams explained that her weight challenges began after the birth of her first daughter

Getty Images

Serena Williams says GLP-1 made her feel light physically and mentally after 31lb loss

Highlights:

  • Serena Williams reveals she has lost more than 31lbs using a GLP-1 medication
  • The tennis legend says the treatment enhanced her existing healthy lifestyle
  • She stresses that weight loss should not change self-image or self-confidence

Serena Williams has revealed she has lost more than 31lbs after turning to a weight-loss medication, saying the treatment has transformed both her body and her mindset.

The 23-time Grand Slam champion, 43, told PEOPLE that using a GLP-1 medication — a type of injection that works by regulating appetite — has helped enhance the healthy lifestyle she already maintained through diet and exercise.

Keep ReadingShow less